ESR1 and cancer: Molecular docking and molecular dynamics simulations provided mechanistic insights into the binding interactions of these derivatives with key cancer-related targets, including Topoisomerase II, VEGFR2, c-Met, EGFR, and Estrogen Receptor Alpha (ERα).